TYVASO DPI IS NOW APPROVED

Skip to main content

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

TAKE CHARGE OF YOUR LUNG HEALTH
Skip to main content

Reclaim the moments that move you

BREATHE THEM IN
WITH TYVASO FOR PH-ILD

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

Catherine’s Story

Hear how TYVASO helped Catherine be more active in her day-to-day life.

Sign up for the Archways program

If you have been prescribed TYVASO for PH-ILD, you can talk to a Virtual Patient Educator* to learn more and receive support through the Archways program.

United Therapeutics and the Archways program do not provide medical advice. You are advised to consult with your healthcare provider with any specific questions or concerns about your treatment.

Co-Pay Assistance Program

With the TYVASO Co-Pay Assistance Program, most eligible patients pay as little as a $0 co-pay for each prescription of TYVASO or TYVASO DPI.

How TYVASO can help

TYVASO increases your ability to be active, reduces the amount of strain on your heart, and decreases the chance of PH-ILD getting worse.